These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 36626829

  • 1. Dynamics of Irreversible NO Release from Photoexcited Molsidomine.
    Yoon H, Park S, Lim M.
    J Phys Chem Lett; 2023 Jan 19; 14(2):516-523. PubMed ID: 36626829
    [Abstract] [Full Text] [Related]

  • 2. New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
    Żorniak M, Mitręga KA, Porc M, Krzemiński TF.
    Can J Physiol Pharmacol; 2017 Feb 19; 95(2):111-121. PubMed ID: 27918857
    [Abstract] [Full Text] [Related]

  • 3. Cyclic GMP mediates SIN-1-induced inhibition of human polymorphonuclear leukocytes.
    Schröder H, Ney P, Woditsch I, Schrör K.
    Eur J Pharmacol; 1990 Jul 03; 182(2):211-8. PubMed ID: 1697805
    [Abstract] [Full Text] [Related]

  • 4. Oxygen and oxidation promote the release of nitric oxide from sydnonimines.
    Bohn H, Schönafinger K.
    J Cardiovasc Pharmacol; 1989 Jul 03; 14 Suppl 11():S6-12. PubMed ID: 2484701
    [Abstract] [Full Text] [Related]

  • 5. Vasorelaxing actions of molsidomine and its metabolites, in comparison with nitroglycerin.
    Muramatsu I, Fujii K, Sakakibara Y, Fujiwara M.
    Can J Physiol Pharmacol; 1983 Sep 03; 61(9):1071-8. PubMed ID: 6416660
    [Abstract] [Full Text] [Related]

  • 6. Modulation of platelet function by SIN-1A, a metabolite of molsidomine.
    Wautier JL, Weill D, Kadeva H, Maclouf J, Soria C.
    J Cardiovasc Pharmacol; 1989 Sep 03; 14 Suppl 11():S111-4. PubMed ID: 2484687
    [Abstract] [Full Text] [Related]

  • 7. An impurity present in some samples of SIN-1 oxidizes it to nitric oxide in anaerobic solutions.
    Wang Y, Rochelle LG, Kruszyna H, Kruszyna R, Smith RP, Wilcox DE.
    Toxicology; 1994 Mar 11; 88(1-3):165-76. PubMed ID: 8160198
    [Abstract] [Full Text] [Related]

  • 8. The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.
    Darius H, Ahland B, Rücker W, Klaus W, Peskar BA, Schrör K.
    J Cardiovasc Pharmacol; 1984 Mar 11; 6(1):115-21. PubMed ID: 6199592
    [Abstract] [Full Text] [Related]

  • 9. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
    Meinertz T, Brandstätter A, Trenk D, Jähnchen E, Ostrowski J, Gärtner W.
    Am Heart J; 1985 Mar 11; 109(3 Pt 2):644-8. PubMed ID: 3838400
    [Abstract] [Full Text] [Related]

  • 10. Oxidative/Nitrative Mechanism of Molsidomine Mitotoxicity Assayed by the Cytochrome c Reaction with SIN-1 in Models of Biological Membranes.
    Paes de Barros M, Casares Araujo-Chaves J, Marlise Mendes Brito A, Lourenço Nantes-Cardoso I.
    Chem Res Toxicol; 2020 Nov 16; 33(11):2775-2784. PubMed ID: 32706246
    [Abstract] [Full Text] [Related]

  • 11. Cyclic GMP as the mediator of molsidomine-induced vasodilatation.
    Kukovetz WR, Holzmann S.
    Eur J Pharmacol; 1986 Mar 11; 122(1):103-9. PubMed ID: 3007172
    [Abstract] [Full Text] [Related]

  • 12. [Effects of SIN-1, a metabolite of molsidomine, on paf-acether-blood platelets interactions].
    Nunez D, Russo-Marie F, Benveniste J.
    Pathol Biol (Paris); 1987 Feb 11; 35(2 Pt 2):215. PubMed ID: 3550639
    [Abstract] [Full Text] [Related]

  • 13. The effects of the nitric oxide donors molsidomine and SIN-I on human polymorphonuclear leucocyte function in vitro and ex vivo.
    Darius H, Grodzinska L, Meyer J.
    Eur J Clin Pharmacol; 1992 Feb 11; 43(6):629-33. PubMed ID: 1337322
    [Abstract] [Full Text] [Related]

  • 14. Active and passive changes in coronary diameter after vasodilation with SIN-1, the active metabolite of molsidomine.
    Schulz W, Kober G, Bernauer R, Kaltenbach M.
    Am Heart J; 1985 Mar 11; 109(3 Pt 2):694-9. PubMed ID: 3838406
    [Abstract] [Full Text] [Related]

  • 15. Molsidomine inhibits the chemoattractant-induced respiratory burst in human neutrophils via a no-independent mechanism.
    Ervens J, Seifert R.
    Biochem Pharmacol; 1992 Aug 18; 44(4):637-44. PubMed ID: 1324680
    [Abstract] [Full Text] [Related]

  • 16. The new long-acting coronary artery dilator molsidomine and its metabolite SIN-1.
    Sobolski J, Vandermoten P, Stoupel E, Berkenboom G, Degre S.
    Am Heart J; 1985 Mar 18; 109(3 Pt 2):700-3. PubMed ID: 3838407
    [Abstract] [Full Text] [Related]

  • 17. Photoactivation of the nitric oxide donor SIN-1.
    Ullrich T, Oberle S, Abate A, Schröder H.
    FEBS Lett; 1997 Apr 07; 406(1-2):66-8. PubMed ID: 9109387
    [Abstract] [Full Text] [Related]

  • 18. 3-Morpholino-sydnonimine-induced suppression of human neutrophil degranulation is not mediated by cyclic GMP, nitric oxide or peroxynitrite: inhibition of the increase in intracellular free calcium concentration by N-morpholino-iminoacetonitrile, a metabolite of 3-morpholino-sydnonimine.
    Kankaanranta H, Knowles RG, Vuorinen P, Kosonen O, Holm P, Moilanen E.
    Mol Pharmacol; 1997 May 07; 51(5):882-8. PubMed ID: 9145927
    [Abstract] [Full Text] [Related]

  • 19. Cerebrovascular effects of nitric oxide manipulation in spontaneously hypertensive rats.
    Fouyas IP, Kelly PA, Ritchie IM, Whittle IR.
    Br J Pharmacol; 1997 May 07; 121(1):49-56. PubMed ID: 9146886
    [Abstract] [Full Text] [Related]

  • 20. [Anti-ischemic effects of SIN-1, a molsidomine metabolite, during coronary angioplasty and antiplatelet effects in humans].
    Darius H, Erbel E, Schmucker B, Reusch U, Meyer J.
    Presse Med; 1988 May 25; 17(20):1033-6. PubMed ID: 2969099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.